

A

Abdominal circumference (AC)

femur length and, 84–85

HC ratio and, 84–85

in IUGR, 83–84

sensitivity of, 83

AIDS, IUGR incidence in, 113

Alcohol

IUGR and, 208

placental clearance of, 7

Alpha fetoprotein (AFP), in IUGR, 98

Amino acids

fetal metabolism of, 53–55, 297, 298

fetal uptake of, 52–53, 297

oxidation of, 54–55

protein synthesis and, 55–57, 59, 63

Amniotic fluid volume

in IUGR, 87, 90

specific gravity of, 92

Anemia

hemoglobin levels in, 218–219

IUGR and, 150, 176–177, 206, 218

malaria and, 176–177, 221

Appropriate for gestational age (AGA)

BW in, 67, 129

DHA-S values in, 102–103,

104–105

estrogens in, 100–101, 104–105

growth charts and, 70, 74

hPL values in, 97, 104–105

IUGR infant comparison, 285–287

nutrient utilization in, 285–289

perinatal mortality and, 128, 129,

279

Asphyxia

perinatal morbidity and, 131

in SGA infants, 131

B

Biparietal diameter (BPD)

growth retardation and, 134

in IUGR, 83, 134

sensitivity of, 83

Birth weight (BW), *see also* Low birth weight

AGA and, 67

body length and, 66, 76, 152, 157, 209

food supplements and, 231–232,

234, 237–240

gestational age and, 44–45,

127–130, 149, 183, 212–213

growth and, 65–66

HC and, 76, 152, 209

hPL and, 96–97

interventive deliveries and, 212

IUGR and, 66, 68, 73, 79, 126–127,

143–153, 157–164, 183

maternal age and, 195–196

maternal blood pressure and,

196–197, 206–207

maternal height and, 144, 145–146,

159–160, 193–195

maternal smoking and, 14,

150–151, 163–164, 209

maternal weight and, 159–160,

193–196

neonatal mortality curves and,

124–130, 181, 190

parity and, 146

placental transport and, 44–45

prenatal care and, 160–163

proteinuria and, 206–207

SEL and, 158, 160–163, 193–194

SGA and, 67

skinfold measurements and, 151,

152, 176

Blood pressure

BW and, 206–207

IUGR and, 196–197, 206–207

maternal, 196–197, 206–207

Brain

composition, 296

LBW and, 184

in SGA infants, 290

weight of, 290

Breast feeding

duration of, 235–236

Breast feeding (*contd.*)

- infant BW and, 280
- of LBW infants, 295
- maternal food supplements and, 235-236
- NEC and, 284

C**Cardiovascular system**

- in heart disease, 7
- in pregnancy, 4-6
- vascular resistance and, 4-5

Catecholamines

- fetal stress and, 18-19
- in maternal malnutrition, 20
- UBF effect, 8

Congenital malformations

- IUGR and, 123,124
- perinatal morbidity and, 130
- perinatal mortality and, 124,129

Consanguinity

- LBW and, 147-149
- in developing countries, 147-149

D**Dehydroepiandrosterone-sulfate (DHA-S)**

- AGA and, 102-103,104-105
- estrogens and, 102,103,104-105
- in IUGR, 103,104-105
- metabolic clearance of, 102-104
- SGA and, 102-103,104-105

Delivery management

- anesthesia in, 116,120
- BW and, 212
- fetal pathology and, 113
- FHR and, 113
- interventive, 212
- in IUGR, 111-117,278-279
- labor induction and, 115,122
- neonatal assistance and, 115-116, 119-120
- placental pathology and, 113

site for, 112

- sonographic evaluation and, 118
- time for, 111-113
- in twin pregnancy, 120
- type of delivery and, 114-115, 121-122

Diabetes

- fat metabolism and, 25
- fetal, 25-26
- maternal, 25,298-299

E**Estriol (E₃)**

- assay of, 99,108
- hPL and, 101-102
- in IUGR, 99-100,101,104-105, 108-109
- placental, 98
- plasma levels, 101-102
- urinary estrogens and, 99-100

Estrogens

- in AGA, 100-101
- assay of, 99
- E₃ as, 98,99-100
- hPL and, 101-102
- in IUGR, 98-102,104-105
- normal pregnancy values, 98-99
- in SGA, 100-101
- in sulfatase deficiency, 102
- urinary, 98-99

F**Femur length**

- AC and, 84-85
- in IUGR, 84-85

Fetal

- acidosis, 121
- biophysical profile, 89-90,93
- body composition, 34,35
- bradycardia, 18
- breathing, 89-90,93
- cardiovascular system, 80-81
- cord blood sampling, 117-118

- death, 119
- diabetes, 25
- diastolic blood flow, 121
- fat content, 58
- fat metabolism, 25,57-58,63-64,
287-288,295-296
- growth pattern, 265-266
- growth retardation, 62
- malformations, 119
- metabolic rate, 41,47-48,58-59
- movements, 89-90
- nutritional requirements, 281-291,
296-297
- oxygen consumption, 7,40,44,
47-48,259
- stress, 18-19
- weight, 25,34
- Fetal energy metabolism
 - fat deposition and, 41-42,296
 - gestational age and, 41
 - glucose metabolism and, 48-53,
58-59
 - glucose uptake and, 44,45,46,47,50
 - growth and, 39,40-41,297
 - growth retardation and, 43-44
 - insulin and, 51-53
 - lactate and, 53
 - maternal factors in, 151-152
 - maternal food supplements and,
228,229,230,232-234
 - metabolic rate and, 41,47-48
 - placenta and, 43-47
 - tissue components and, 40-41
- Fetal fat metabolism
 - fat content and, 57-58
 - fat deposition and, 41-43,296
 - fat excretion and, 285-286
 - fat transport and, 64
 - gestational age and, 41-42
 - intake and, 285-286
 - of MCT, 295-296
 - placenta and, 63-64
- Fetal glucose metabolism
 - energy requirements and, 48,58-59
 - fetal utilization and, 48-49,58-59
 - glucose sources and, 48-50
 - growth regulation and, 50,58-59
 - hypoglycemia and, 62
 - insulin and, 51-53
 - IUGR and, 216-217
 - lactate and, 64
 - maternal glucose and, 48-49
 - rate of, 50-52
 - umbilical glucose uptake and,
48-49
- Fetal growth
 - in AGA infant, 67
 - body fat and, 23,24,41-43
 - body length and, 66,76
 - classification, 133-135,136-137
 - endocrine assessment of, 95
 - energy metabolism and, 39,40-41
 - genetically retarded, 291
 - gestational age and, 39,40-41
 - GH effects, 23-25
 - growth charts and, 68-70,73
 - hormonal regulation of, 23-30
 - hypophysectomy and, 24-25
 - IGF and, 27-30,34-35
 - insulin and, 25-27,33
 - maternal factors in, 14
 - maternal nutrition and, 75-76,219,
223,234-235,263-265
 - metabolic rate and, 41,47-48
 - normal, 126-127
 - oxygen consumption and, 40
 - placenta and, 33-34,35,43-47
 - protein accretion in, 39
 - protein synthesis and, 56-57
 - PTH and, 33
 - regulation of, 34-35,39,50,58-59
 - retardation, 43-44,62,63,67-68,
73,126-127,133-135,
136-137
 - SGA and, 67-68
 - sonographic evaluation of, 82-87
 - standards for, 125-126
 - thyroid hormone and, 24,25
 - UBF and, 9-10,20
 - utero-placental perfusion and, 9-11

Fetal growth curves

- AGA and, 67,70,74
 - birth length and, 76
 - birth order and, 70-71
 - BW and, 65-66,67,125
 - definitions in, 65-66,75
 - factors influencing, 70-71,74, 75-77
 - fetus at risk identification and, 68, 75-77
 - gestational age and, 84,86
 - in growth retardation, 67-68,73, 75-77
 - identification of SGS fetus and, 66-67
 - in IUGR, 66,73,125,219
 - ponderal index and, 73
 - SGA and, 67-68
 - velocity and, 75
- Fetal heart rate (FHR), timing of delivery and, 113**
- Fetal protein metabolism**
- amino acid metabolism and, 53-55, 59,63,296-297,298
 - amino acid uptake and, 52-53,297
 - gestational age and, 56-57,59
 - growth and, 56-57
 - organ differences in, 56-57
 - protein accretion and, 39,53-54,57, 296-297
 - in protein deprivation, 57,63
 - synthesis rate and, 55-57,59
 - urea production and, 53-54
- Feto-placental circulation**
- cardiac output and, 12
 - diagram of, 12
 - regulation of, 11-13
 - vasoactive agents and, 13
- Food supplements**
- breast feeding and, 235-236
 - BW influence on, 231-232,234, 237-240,263-265
 - composition of, 227,228
 - consumption of, 225

- energy level of, 228,229-230, 232-234,238-239
- gestational age and, 238-239
- IUGR and, 240
- maternal weight gain on, 231,235
- perinatal mortality and, 223-224, 234-235
- period of, 231,238-239
- program for, 225-228,238-239
- quality of, 225
- recipient's diet and, 224,225, 229-230
- regimen in, 228,238-239
- SEL and, 228-229
- a seven-country summary of, 237-241

G**Gestational age**

- BW and, 44-45,125-126, 127-130,147-149,167,183, 187-189,212-215
 - caloric requirements and, 41
 - delivery date and, 213
 - fat metabolism and, 41-43
 - fetal growth rate and, 39-40,42-43
 - fetal protein synthesis and, 56-57
 - HC/AC ratio and, 84
 - hPL and, 96
 - interventive delivery and, 212
 - IUGR and, 86,125-126,147-149, 167,186,211-216
 - nitrogen content and, 42-43
 - nonfat dry weight and, 42-43
 - placental blood flow and, 3-5
 - TPN and, 248
 - uterine blood flow and, 3-4,5-6
 - uterus size and, 81,227
 - uterus weight and, 5-6
- Growth hormone**
- fetal growth and, 23-25
 - of fetal origin, 23-24
 - IGFs and, 28
 - maternal, 23

H

Head circumference (HC)
AC ratio, 84–85
body length and, 76,189,191
BW and, 75,76,133,134,152,189,
191
gestational age and, 84
of Indian infants, 189,191
in IUGR, 83–84,133,134,269
maternal smoking and, 209
sonographic evaluation of, 82–83

Human placental lactogen (hPL)
BW and, 96,97,104–105
developing country use of, 168
estrogens and, 101–102
gestational age and, 90
IUGR and, 95–98,101–102,
104–106,108–109
measurement of, 96
perinatal mortality and, 96–97
placental synthesis, 95–96
mRNA for, 98

Hypertension, maternal, 150

Hyperviscosity
definition of, 141
in IUGR, 131
perinatal morbidity and, 131,
132–133,141
treatment, 141

Hypoglycemia
causes of, 132,282
in IUGR, 132,216–217,282
neonatal, 282–283
perinatal morbidity and, 132,142

Hypoxia
fetal response to, 13,18
perinatal morbidity and, 131
umbilical blood flow and, 8

I

Infant mental development
IQ and, 270,271
of IUGR infants, 269–273

maternal conditions of pregnancy
and, 271
neonatal medical conditions and,
271–272
of preterm infants, 270

Insulin
diet and, 36
fetal glucose metabolism and,
51–53,216–217,298–299
fetal growth and, 25–27,33,35–36,
299

hyperinsulinemia and, 26
hypoinsulinemia and, 26
lipid deposition and, 25,33

Insulin-like growth factors (IGFs)
autocrine/paracrine functions of,
29–30
carrier forms of, 27–28
effects of, 34
endocrine control of, 28
fetal growth and, 27–30,33,34–35
gestational age and, 27
GH and, 28
nomenclature, 27
placenta and, 29,36
plasma concentrations of, 27–28
receptor, 33
sources of, 28–29

Intervillous blood flow (IVBF), IUGR
and, 10–11

Intra-amniotic nutrition
in IUGR, 253–254,258
utero malnutrition and, 253–254,
258

Intrauterine growth retardation (IUGR)
AC in, 83–84
AFP in, 98
in Africa, 165–178
AIDS and, 113
amniotic fluid volume and, 87,92
anemia and, 150,176–177,206,218
in Bangladesh, 183,184,193–197
biophysical profile in, 89,93
blood pressure and, 206,221–222

Intrauterine growth retardation (IGFs)*(contd.)***BPD in, 83,134****in Brazil, 157–164,277****BW and, 66,68,73,79,85–87,
126–127,143–153,157–164,
183,188–191,199–202,221,
261–263****cerebral resistance index in,
120–121****classification of, 123–124****congenital malformations in, 123,
124,130,214–215****consanguinity and, 147–149****definition of, 79,124–125,126–127****delivery management in, 111–117,
118–121,278–279****DHA-S values in, 102–103****diagnosis of, 81–82,87,89,95****E₃ and, 99–100,101,104–105,
108–109****energy metabolism in, 111–117,
278–279****estrogens in, 98–102****etiology of, 79–80,108–109,
143–153,205–207,208,
214–217****femur length in, 84–85****fetal growth pattern in, 265–266****fundal growth and, 81,97****gestational age and, 86,125–126,
147–149,167,186–189,
211–216,221****GI development in, 284****growth curves in, 66,68,73,125,219****HC in, 83–84****HC/AC in, 84–85****hPL detection of, 95–98,101–102,
104–106****hypertension and, 118,121,150,219****hyperviscosity and, 131,132–133,141****hypoglycemia in, 131,132,
216–217,282****hypothermia and, 131,133****incidence of, 79,165,261,274****in India, 183,184,186–191****indicators of, 75–76,79–89,95–106****infection and, 214–215,216****intra-amniotic nutrition in, 253–254****in Italy, 205–217****IVBF in, 10–11****LBW and, 79,85–87,95,125–127,
143–153,157–164,183,
188–191,199–202,214–215,
261–262****lung immaturity in, 118****malaria and, 172–175****maternal heart disease and, 7****maternal hypertension and, 118****maternal hypotension and, 20****maternal nutrition and, 175–176,
219,223,263–265,271,
281–282****maternal pathology and, 114,271****maternal weight and, 159–160,
193–196,231,235,266****morbidity in, 123,129,130–136,
141,165,266–267,278****mortality in, 80,123,127–130,220,
278****neonatal assistance for, 115–116****neonatal morbidity in, 266–267****neurological follow up, 279****normal growth and, 126–127****nutritional supplementation and,
219,240,279–280****pathophysiology of, 205–207****PI in, 130–131,135,136,268****placenta and, 113,214,216****plasma volume and, 205–206****prognosis in, 217****pulmonary hemorrhage in, 131–132****pulsatility index and, 13–14,21****mRNA in, 98****SEL and, 158,160–163,188–189,
262,274–275**

- SGA and, 67,95,127,221
 - skeletal growth and, 134,135
 - smoking and, 21,150-151, 163-164,209-211
 - sonographic evaluation of, 79-89, 104-105,118,120,121
 - subgroups of, 133-135,136-137, 265-266,267,271-273
 - symmetry in, 84-85,135
 - TPN in, 244-245,248,252,254
 - twins and, 178,215,216
 - utero malnutrition and, 253-254
 - utero-placental perfusion and, 9-10,205,253
- IUGR in Africa
- anemia and, 176-177
 - BW in, 165-167,172-175
 - epidemiology of, 165-167
 - etiology of, 167
 - gestational age and, 167
 - low BW in, 165
 - malaria and, 169-171,172-175, 176-177
 - placental lesions and, 172,174
 - undernutrition and, 175-176
- IUGR in Bangladesh
- BW in, 190,193-197
 - information sources, 185-186,192, 197
 - LBW in, 185,189-191,197, 199-201
 - maternal characteristics and, 193-195
 - perinatal blood pressure and, 199, 200
 - SEL in, 184-185,199-200
- IUGR in Brazil
- BW and, 157-164,277,280
 - maternal influences, 157-164,277
 - prenatal care and, 160-163
 - SEL and, 158,160-163
 - SFD and, 277,278,280
- IUGR in India
- gestational age and, 187-189
 - information sources for, 185-186, 197
 - LBW and, 185,186-189,197-199
 - length growth and, 189,191
 - neonatal mortality in, 189,190,198
 - newborn anthropometrics, 189,191
 - SEL and, 184,188,189,197-199
 - weight gain of infants and, 189,190
- IUGR infants
- AGA infant comparison, 284-287
 - bone mineralization in, 288-289
 - carbohydrate utilization in, 285-289
 - catch-up growth in, 279-280,289
 - energy metabolism in, 284-285, 289,290-291,295-297
 - fat absorption in, 286-287
 - fat metabolism in, 287-288
 - GI tract of, 284
 - growth retardation in, 273-274, 279-280
 - hypermetabolism of, 289
 - maternal conditions and, 271-272
 - MCT use for, 282-283,295
 - mental development of, 269-273
 - morbidity in, 266-267
 - nutrient utilization in, 285-286
 - physical growth, long-term, 268-269
 - PI of, 268
 - preterm, 269
 - protein absorption in, 285,297
 - protein metabolism in, 285-287, 297
 - SGA infant comparison, 285
 - subgroups of, 266-267,271-273
- IUGR in Italy
- BW and, 209-215
 - causes of, 208,214-217
 - delivery date and, 213
 - gestational age and, 212-215
 - HC in, 209

IUGR in Italy (*contd.*)

- hypoglycemia and, 216–217
 - maternal blood pressure and, 206–207
 - maternal smoking and, 209–211, 214, 215
 - risk factors in, 205–217
- IUGR in neonates
- adipose tissue content of, 283
 - energy requirements of, 282
 - extrauterine adaptation of, 282–284
 - MCT feeding of, 282–283
 - mortality, 234–235
 - NEC development in, 284
 - nutritional requirements of, 284–290
 - preterm infants and, 235

L

Lactate

- fetal metabolism, 64
 - glucose metabolism and, 64
- Low birth weight (LBW)
- in Africa, 165–167, 172–175
 - brain in, 184
 - breast feeding of, 295
 - causes of, 79–80, 143–153, 167
 - consanguinity and, 147, 148–149
 - definition of, 124–126, 143
 - in developing countries, 143–153
 - diabetes and, 25
 - fetal nutrition of, 296
 - genetic influences, 146–147
 - gestational age and, 86, 125–126, 147–149, 167, 183, 187–189, 214–215
 - hPL and, 96–97
 - incidence of, 165, 184, 187, 261
 - in India, 186–189, 197–199
 - in Italy, 205–217
 - IUGR and, 79, 85–87, 95, 125–127, 143–153, 157–164, 183, 188–191, 199–202, 261–265
 - “light-for-date” and, 101

malaria and, 172–175

- maternal height and, 144, 145–146, 264
- maternal nutrition and, 175–176, 219, 223, 243, 263–265
- maternal smoking and, 163–164, 209–211
- mortality and, 127–130, 184
- multiple births and, 126
- neonatal mortality and, 124–125
- in Pakistan, 144–153
- primigravidas and, 173
- SEL and, 158, 160–164, 197–202
- sex and, 193
- sonographic evaluation of, 85–87
- teenage pregnancy and, 177–178
- undernutrition and, 175–176
- uterus and, 81

M

Malaria

- anemia and, 176–177, 221
- BW and, 172–175
- geographic distribution of, 168, 169
- immune response and, 170–171, 220
- IUGR and, 151, 169, 220
- placental, 169, 170, 172, 173, 174–175, 220–221
- pregnancy and, 169–171
- sickle cell disease and, 177

Maternal

- age, 195–196, 222, 266
- blood pressure, 196–197
- blood volume, 5
- BW influence, 144, 145–146, 159, 193–196, 211, 263
- cardiovascular changes, 4–6
- diabetes, 25
- energy balance, 151–152
- fetal circulation, 1–15
- food supplementation, 223–236, 237–240, 243–246, 263–265

- height, 144,145–146,159–160,194,
264
hyperglycemia, 257
hypertension, 20
IUGR risk factors, 82,119
malaria, 151,169–175
malnutrition, 14,19,219,223,
243–246
parenteral alimentation, 243–253
physical activity, 19,211
physical characteristics, 193–195,
265–266
prenatal care, 160–163
SEL and, 193–194
smoking, 193–194
toxemia, 266
UBF, 5–6
undernutrition, 14
uterus, 81
vascular disease, 10
weight, 159–160,193–196,231,
235,266
- Maternal nutrition**
acute vs chronic, 20
blood volume and, 19
energy requirements and, 249,
251–252,254,257
food supplements and, 223–236,
237–240,263
guidelines for, 246–247,249
LBW and, 175–176,219,223,243,
263–265,279
placental circulation and, 14
protein requirements in, 246,
253–254,257,263
TPN as, 243–253
- Medium chain triglycerides (MCT)**
adipose tissue content and, 283
deposition, 296
formulas, 295–296
IUGR infants and, 282–283,
295–296
neonatal feeding of, 282–283,
295–296
- Metabolic rate**
fetal, 41,47–48
oxygen consumption, 7,40,44,
47–48
- N**
Narcotics, IUGR and, 120
Necrotizing enterocolitis (NEC)
breast feeding and, 284
neonatal, 284
Neonatal IUGR infants
medical conditions of, 271–272
mental development of, 271–273
Neonatal morbidity
indicators of, 267
of IUGR subgroups, 266–267
Nutrition, *see also* Maternal nutrition
fetal, 253–254,259
food supplements and, 219,
223–241,243,246
intra-amniotic, 253–254
of IUGR neonates, 284–290
of LBW infants, 296
in pregnancy, 223–236,243,246,
249–250
protein requirements and, 249–250,
253,285–287
in SGA, 281–282
TPN use in, 243–254
- O**
Oxygen consumption
of fetus, 40,44,47–48,259
placental weight and, 43–44
species differences in, 40
UBF and, 7
- P**
Pakistani (Sorrento) infants
consanguinity in, 147–149
gestation age and, 144
LBW of, 144–153

- Pakistani (Sorrento) infants (*contd.*)
 maternal fertility and, 146
 maternal height and, 144,145-146
 maternal influences, 150-153
- Parathyroid hormone (PTH), fetal
 growth and, 33
- Perinatal morbidity
 asphyxia and, 131
 BW and, 129,136
 complications in, 130-133,
 135-136
 congenital malformations and, 130
 hyperviscosity and, 131,132-133,
 141
 hypoglycemia and, 131,132
 hypothermia and, 131,133
 in IUGR, 123,129,130-136,141
 maternal smoking and, 210
 pathophysiology in, 136-137
 pulmonary hemorrhage and,
 131-132
- Perinatal mortality
 BW and, 124-125,127-130,190
 etiology of, 124-125,128-129
 fetal age and, 128
 in growth retardation, 127-130
 hPL and, 96-97
 in India, 189,190
 in IUGR, 80,123,127-130,220,
 271-273
 maternal nutrition and, 223-224,
 234-235,271-272
 pneumonia and, 124
 prediction of, 130
- Placenta
 alcohol clearance of, 7
 BW and, 44-45
 circulation in, 1-5
 DHA-S and, 102,103
 fat transport in, 64
 fetal growth and, 33-34,35,43-47,
 62
 glucose transfer in, 44-45,46,47
 growth of, 3
 hPL production, 95-98
 IGF and, 29,36
 in IUGR, 113,214,216
 lesions of, 172
 malaria and, 169,170,174-175
 ovine, 3
 pathology of, 113
 pigmented, 174
 size of, 62
 transport, 6-7,43,44-47
 UBF and, 3-7,46
 weight, 14,43-44,152
- Placental circulation
 anatomy of, 3-4,5
 fetal growth and, 1-5
 gestational age and, 3-5
 maternal malnutrition and, 14
 maternal smoking and, 14
- Ponderal index (PI)
 in IUGR, 130-131,135,136,267,
 268
 in SGA, 136
- Pregnancy
 cardiovascular changes in, 4-6
 early, 146-147
 food supplements during, 223-236,
 237-241,246,263
 late, 147
 lipid requirements in, 246-247
 malaria and, 169-175
 malnutrition in, 14,19,219,223,
 243,246,253-254,282-284
 nutritional guidelines for, 246-247,
 249,263-265
 plasma volume in, 243
 previous pregnancy and, 144,146
 protein requirements in, 246,
 253-254,257
 smoking in, 14,21,126,150-151,
 163-164,209-211,214,215
 of teenagers, 177-178
 TPN in, 243-253,258
 twins in, 120
- Prenatal care

BW and, 160–163
 SEL and, 160–163
 Prolactin, fetal growth and, 34
 Prostaglandins (PG), UBF and, 8
 Pulmonary hemorrhage
 in IUGR, 131–132
 perinatal morbidity and, 131–132

R

Ritodrine, uterine-placental perfusion
 and, 6–7
 mRNA
 for hPL, 98
 in IUGR pregnancies, 98

S

Small for delivery (SFD)
 catch-up growth in, 298
 diet and, 295,296,297,298
 energy requirements for, 297,298
 Small-for-gestational age (SGA)
 birth length and, 76
 brain weight of, 290
 BW of, 67,95
 catch-up growth in, 290
 criteria for, 68,70,73,74,221
 DHA-S values in, 102–103,
 104–105
 energy intake of, 285,290
 estrogens in, 100–101,104–105
 excretion losses in, 285
 hPL values in, 97,104–106
 hypermetabolism of, 289
 IUGR and, 67,95,127
 management of, 141–142,279
 maternal nutrition and, 281–282
 perinatal mortality and, 128,129
 PI in, 136
 T cell function in, 173
 types of growth retardation in,
 67–68

Smoking

fetal body length and, 209
 fetal BW and, 163–164,209–211,
 214,215
 fetal HC and, 209
 fetal pathology and, 21
 index of, 222
 infant growth and, 211
 IUGR and, 21,150–151,163–164,
 209–211
 maternal, 14,21,126,150–151,
 163–164,209–211,214,215
 passive, 21
 perinatal death and, 210
 placental weight and, 211
 SDS and, 21
 SEL and, 164
 UBF and, 14
 volume of, 209
 Socioeconomic level (SEL)
 age at marriage and, 193–194
 in Bangladesh, 184–185,199–201
 in Brazil, 158,160–163
 BW and, 158,160–164,184,
 197–202
 fetal growth and, 163
 food supplements and, 228–229
 gestational age and, 188,189
 in India, 184,188,189,197–199
 IUGR and, 158,160–163,188–189,
 262,274–275
 maternal characteristics and,
 193–194
 perinatal blood pressure and, 199,
 200
 prenatal care and, 160–163
 smoking and, 164
 Somatomedin, *see* Insulin-like growth
 factors (IGFs)
 Sonographic evaluation
 of AC, 83–84
 of BPD, 83
 of cardiovascular system, 80–81
 computer analysis of, 88–89
 cost of systems, 88

Sonographic evaluation (*contd.*)

- of fetal growth, 80,82-87
- of fetal symmetry, 84-85
- of fetal weight, 83,85-87
- of fetal well-being, 89
- of HC, 83-84
- of IUGR, 79-89,104-105,118, 120,121
- problems of, 121
- routine use of, 87-88,118
- sensitivity of, 83,88

Species differences

- in fetal fat content, 58
- in fetal growth, 39
- in fetal oxygen consumption, 40

Sudden death syndrome (SDS), smoking and, 21

T

Thyroid hormone

- fetal growth and, 24,25
- fetal thyroidectomy and, 25

Total parenteral nutrition (TPN)

- carbohydrates in, 248-249
- components of, 248-251
- duration of, 247
- electrolytes in, 251,252
- energy requirements in, 249, 251-252,257
- fat in, 250
- gestational age and, 248
- heparin in, 251
- indications for, 247,258
- in IUGR, 244-245,248,252
- in pregnancy, 243-252,254,258
- protein in, 249-250,252
- safety of, 252-253
- variables in, 248-249
- vitamins in, 250,251

U

Ultrasound, *see* Sonographic evaluation

Umbilical circulation

- critical level for, 20
- fetal growth and, 11,20,46
- regulation of, 11-13

Uterine blood flow (UBF)

- cardiac output and, 3-4
- catecholamine effect, 8
- fetal asphyxia and, 131
- fetal oxygen uptake and, 7
- gestational age and, 3-4,5-6
- IUGR and, 10
- placenta and, 3-7,46
- in pregnancy, 3-7
- regulation of, 8-9

Utero-placental blood flow

- alteration of, 9-11
- anatomy of, 3-4
- blood pressure and, 2,3
- cardiac output and, 3
- catecholamines and, 8
- fetal growth and, 9-11,20
- IUGR and, 9-11,205,253
- ovine, 3,5
- PG and, 8
- placental transport and, 6-8,20-21
- regulation of, 8-9
- ritodrine effect, 6-7
- smoking and, 14

Uterus

- blood flow in, 3-4,5-6
- fundus measurement of, 81,97
- gestational age and, 3-4,5-6,81
- innervation, 9
- IUGR and, 81
- oxygen delivery to, 7
- weight of, 5-6